



September 27, 2024

To: All Concerned Parties

Company Name: Solasia Pharma K.K.
Representative: Yoshihiro Arai, President & CEO
(Code number: 4597, TSE Growth Section)
Contact: Toshio Miyashita, CFO, Director
Tel: 81-3-5843-8046
URL: <https://solasia.co.jp/en/>

Solasia Announces Notice of Status of Progress in Out-licensing SP-02 (DARVIAS[®]) in China

Solasia Pharma K.K. announces that it has reviewed the expected timing of the conclusion of a licensing agreement for DARVIAS[®] (development code: SP-02, generic name: darinaparsin, hereinafter referred to as "DARVIAS[®]") in China.

Currently, negotiations with several Chinese pharmaceutical companies that are candidates for DARVIAS[®] out-licensing are progressing toward the conclusion of an agreement.

It took us some time to confirm the opinion from the Chinese authorities on the design of the clinical trials required for the NDA of DARVIAS[®] in China, and we were only able to confirm the opinion from the authorities in September of this year. Therefore, we have decided to change the expected out-licensing timing of DARVIAS[®] to the end of December 2024. We will proceed with negotiations toward the conclusion of the agreement diligently.

The reviewing of the expected timing of the DARVIAS[®] licensing agreement will have no impact on the Solasia consolidated financial forecast for FY2024.

Disclaimer: The forward-looking statements, including earnings forecasts, contained in this press release are based on information currently available to the Company and on certain assumptions deemed to be reasonable. Such statements should not be construed as representing commitments on the part of the Company. Please be aware that actual performance may differ for a variety of reasons. Major factors affecting the Company's actual performance include the economic conditions in which it operates, exchange rate fluctuations, the competitive situation and other factors. Information contained in this press release is for informational purposes only and should not be considered as investment solicitation. Information with regard to pharmaceuticals and medical devices (including products under development) is not provided for the purposes of advertising or medical advice. We do not have any obligation to update or revise any information in this press release, and any update or revision may occur anytime without notice.